Kathryn F. Mileham, MD, FACP

In this article, important concepts in the molecular testing of non–small-cell lung cancer are highlighted.

This review will describe the well-known use of VEGF antibodies; the current uses of EGFR and ALK tyrosine kinase inhibitors; newer agents being used against MET, FGFR, and other intracellular targets; insights regarding the field of immunotherapy in lung cancer; and finally, newer developments in chemotherapy.